​

Aligos Therapeutics (ALGS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ALGS Stock Forecast

Aligos Therapeutics (ALGS) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $20.00, with a high of $20.00 and a low of $20.00. This represents a 132.83% increase from the last price of $8.59.

- $8 $16 $24 $32 $40 High: $20 Avg: $20 Low: $20 Last Closed Price: $8.59

ALGS Stock Rating

Aligos Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (60.00%), 2 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 2 3 Strong Sell Sell Hold Buy Strong Buy

ALGS Price Target Upside V Benchmarks

TypeNameUpside
StockAligos Therapeutics132.83%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts111
Avg Price Target$20.00$20.00$20.00
Last Closing Price$8.59$8.59$8.59
Upside/Downside132.83%132.83%132.83%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2613---4
Dec, 2513---4
Nov, 2522---4
Oct, 2522---4
Sep, 2522---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 07, 2026Michael YeeUBS$20.00$8.76128.31%132.83%
Jan 06, 2023Piper Sandler$3.00$1.22145.90%-65.08%
Jan 06, 2023Jefferies$3.00$0.99203.03%-65.08%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 07, 2026UBSBuyinitialise
Sep 20, 2024H.C. WainwrightBuyBuyhold
Sep 12, 2024Piper SandlerOverweightOverweighthold
Aug 19, 2024H.C. WainwrightBuyinitialise
Jul 19, 2024Piper SandlerOverweightOverweighthold
May 17, 2024Piper SandlerOverweightOverweighthold
Jan 06, 2023BarclaysEqual-Weightdowngrade
Jan 06, 2023Piper SandlerOverweightupgrade
Nov 03, 2022SVB LeerinkMarket PerformMarket Performhold

Financial Forecast

EPS Forecast

$-150 $-120 $-90 $-60 $-30 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.22$-2.25$-3.52$-20.94----
Avg Forecast$-78.73$-53.13$-34.25$-10.09$-11.92$-13.14$-15.68$-5.53
High Forecast$-61.97$-49.31$-30.93$-8.97$-8.13$-6.82$-7.57$-5.53
Low Forecast$-108.73$-60.76$-37.57$-11.21$-17.88$-19.46$-23.79$-5.53
Surprise %-95.91%-95.77%-89.72%107.53%----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.36M$13.91M$15.53M-----
Avg Forecast$4.00M$12.55M$14.40M$3.73M$1.33M$32.50M$122.00M$239.01M
High Forecast$5.17M$13.94M$15.97M$4.58M$1.33M$32.50M$122.00M$239.01M
Low Forecast$3.34M$11.86M$12.82M$3.31M$1.33M$32.50M$122.00M$239.01M
Surprise %9.02%10.81%7.84%-----

Net Income Forecast

$-7B $-6B $-4B $-3B $-1B $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-128.33M$-96.05M$-87.68M$-131.21M----
Avg Forecast$-5.06B$-1.32B$-851.92M$-251.06M$-323.39M$-326.84M$-390.02M$-137.55M
High Forecast$-3.98B$-1.23B$-769.31M$-223.19M$-202.17M$-169.64M$-188.29M$-137.55M
Low Forecast$-6.99B$-1.51B$-934.53M$-278.92M$-444.61M$-484.04M$-591.74M$-137.55M
Surprise %-97.46%-92.73%-89.71%-47.74%----

ALGS Forecast FAQ

Is Aligos Therapeutics stock a buy?

Aligos Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Aligos Therapeutics is a favorable investment for most analysts.

What is Aligos Therapeutics's price target?

Aligos Therapeutics's price target, set by 5 Wall Street analysts, averages $20 over the next 12 months. The price target range spans from $20 at the low end to $20 at the high end, suggesting a potential 132.83% change from the previous closing price of $8.59.

How does Aligos Therapeutics stock forecast compare to its benchmarks?

Aligos Therapeutics's stock forecast shows a 132.83% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Aligos Therapeutics over the past three months?

  • January 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Aligos Therapeutics’s EPS forecast?

Aligos Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-11.92, marking a -43.08% decrease from the reported $-20.94 in 2024. Estimates for the following years are $-13.14 in 2026, $-15.68 in 2027, and $-5.53 in 2028.

What is Aligos Therapeutics’s revenue forecast?

Aligos Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $1.33M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $32.5M, followed by $122M for 2027, and $239.01M for 2028.

What is Aligos Therapeutics’s net income forecast?

Aligos Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-323M, representing an 146.47% increase from the reported $-131M in 2024. Projections indicate $-327M in 2026, $-390M in 2027, and $-138M in 2028.